As a typical representative of aging-related skeletal muscle degenerative diseases, sarcopenia (SP) relies heavily on animal models for advancing basic and clinical research. Traditional Chinese Medicine (TCM), based on the theory of "flaccidity syndrome," exhibits unique advantages in treating SP, whereas modern medicine currently lacks specific therapeutic options. A standardized evaluation system integrating TCM and Western medicine is crucial for accelerating SP research. Current SP animal models face the challenge of failing to fully reflect the multifactorial etiology of the disease. Developing a multi-factor combined model that better mimics clinical heterogeneity is key to addressing this limitation. This study systematically summarizes and evaluates the strengths and weaknesses of existing SP animal models. Based on the clinical pathological mechanisms of SP and TCM syndrome classifications for SP treatment, we established integrated TCM-Western clinical diagnostic criteria for SP. Furthermore, we innovatively propose a multi-level TCM-Western evaluation system for SP animal models, encompassing phenotypic, functional, syndrome characteristic, and molecular marker levels. Through clinical concordance analysis, the feasibility of a "combined modeling method was verified. Among existing SP models, aging models showed an 70% concordance rate but lacked TCM syndrome characteristics. Induced models and surgical models, despite strong timeliness, only achieved a 40%-55% clinical concordance rate. The proposed "combined modeling method for SP animal models can simultaneously simulate the natural aging process and TCM syndrome features of muscle atrophy caused by "spleen deficiency and "kidney deficiency." The integrated TCM-Western medicine-guided construction process for SP animal models provides methodological support for analyzing the "disease-syndrome-target relationship and screening targeted drugs, which will promote the internationalization of TCM-based anti-SP research.